The Phase 2 failure in major depressive disorder marks the second time in a little more than a year that Neurocrine Biosciences has reported a drug licensed from Takeda Pharmaceutical fell short in the clinic. Last year, a different drug from this partnership failed a mid-stage test in schizophrenia.
The post Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression appeared first on MedCity News.
